Methylene Blue Administration Reduces Acute Kidney Injury After Living Donor Liver Transplantation: A Single-Center Retrospective Study. (2026)

Peer-Reviewed Study · Katayama A, Abuelkasem E, Longhitano Y, Planinsic RM, Smith AC, Wang DW · March 8, 2026

Katayama A et al., 2026-03-08: Retrospective cohort of 415 living-donor liver transplant patients in which pre-reperfusion methylene blue was associated with less stage 1 acute kidney injury and less early allograft dysfunction.

MB just prior to graft reperfusion was associated with decreased incidence of postoperative AKI stage 1 in LDLT.

Katayama A et al., 2026-03-08: Retrospective cohort of 415 living-donor liver transplant patients in which pre-reperfusion methylene blue was associated with less stage 1 acute kidney injury and less early allograft dysfunction. C10 (renal, human observational). Study type: retrospective cohort, N=415, living-donor liver transplantation January 2018 – June 2023; Department of Anesthesiology and Perioperative Medicine (country not stated in the abstract; authors' institution per journal listing). Dose: methylene blue given just before graft reperfusion; the abstract does not give mg/kg. Comparator: patients not receiving methylene blue (historical/observational). Funder/conflicts not stated in the abstract. Observational association only. Health Sci Rep 2026;9:e72025. Study type: controlled study.